NLG919

Home
Ligands
NLG919

Ligand id: 9019

Name: NLG919

Structure and Physico-chemical Properties

2D Structure

Calculated Physico-chemical Properties
Hydrogen bond acceptors	3
Hydrogen bond donors	1
Rotatable bonds	3
Topological polar surface area	38.05
Molecular weight	282.17
XLogP	4.55
No. Lipinski's rules broken	0

Molecular properties generated using the CDK

Classification
Compound class	Synthetic organic

IUPAC Name
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

IUPAC Name

1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

Synonyms
GDC-0919 \| NLG 919 \| RG6078

Synonyms

GDC-0919 | NLG 919 | RG6078

Database Links
CAS Registry No.	1402836-58-1 (source: PubChem)
GtoPdb PubChem SID	315661104
PubChem CID	66558287
Search Google for chemical match using the InChIKey	YTRRAUACYORZLX-UHFFFAOYSA-N
Search Google for chemicals with the same backbone	YTRRAUACYORZLX
Search UniChem for chemical match using the InChIKey	YTRRAUACYORZLX-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone	YTRRAUACYORZLX
SynPHARM	83385 (in complex with indoleamine 2,3-dioxygenase 1)

Comments
NLG919 is a potent inhibitor of indoleamine-2,3-dioxygenase (IDO1). IOD1 the first and rate-limiting component of the pathway mediating metabolism of tryptophan to kynurenine. Tryptophan depletion enhances the number and function of the T_reg (suppressive) arm of the immune system and inhibits the effector T cell (stimulatory) arm. This action of IDO1 facilitates acquired local and peripheral immune tolerance in normal and pathological conditions. IOD1 inhibitors are being developed as novel therapeutics to reverse the immunosuppression associated with cancer.

Comments

NLG919 is a potent inhibitor of indoleamine-2,3-dioxygenase (IDO1). IOD1 the first and rate-limiting component of the pathway mediating metabolism of tryptophan to kynurenine. Tryptophan depletion enhances the number and function of the T_reg (suppressive) arm of the immune system and inhibits the effector T cell (stimulatory) arm. This action of IDO1 facilitates acquired local and peripheral immune tolerance in normal and pathological conditions. IOD1 inhibitors are being developed as novel therapeutics to reverse the immunosuppression associated with cancer.